Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03864666 · ClinicalTrials.gov registry record · Phase 1
Bioequivalence Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers
A Phase 1 study, sponsored by Genovate Biotechnology Co., Ltd.,.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT03864666: Completed Phase 1 study, sponsored by Genovate Biotechnology Co., Ltd.,.
NCT03864666 is a Phase 1 study that has completed, run by Genovate Biotechnology Co., Ltd.,. The registered enrollment target is 28 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03864666, a Phase 1 study, has completed, sponsored by Genovate Biotechnology Co., Ltd.,.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The study is designed to evaluate the bioequivalence and the within-subject variability between the test formulation of extended-release tablet of cilostazol (PMR) administered once daily and the reference formulation of immediate-release tablet of cilostazol (Cilostazol) administered twice-daily in normal healthy male and female subjects under fasting conditions.
Interventions
- DRUG Cilostazol 100 mg
- DRUG PMR 200 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2019-02-11 |
| Est. Completion | 2019-05-03 |
| Phase | Phase 1 |
What the finished NCT03864666 record still lists
NCT03864666 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 2 interventions - of which Cilostazol 100 mg is the first listed.
NCT03864666 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03864666 about?
NCT03864666 is a clinical study titled "Bioequivalence Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers". The study is designed to evaluate the bioequivalence and the within-subject variability between the test formulation of extended-release tablet of cilostazol (PMR) administered once daily and the reference formulation of immediate-release tablet of cilostazol (Cilostazol) administered twice-daily in...
What is the current status of trial NCT03864666?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2019-02-11. Estimated completion is 2019-05-03.
What interventions are being tested in trial NCT03864666?
The interventions under investigation include: Cilostazol 100 mg (DRUG), PMR 200 mg (DRUG).
Who is sponsoring clinical trial NCT03864666?
This trial is sponsored by Genovate Biotechnology Co., Ltd.,, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03864666's enrollment target sits among peer trials
28 1447th of 2000 higher than 538 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI